Who is eligible for GIPAP™?
GIPAP is accessible to eligible patients who:
- are properly diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid
leukaemia (CML) patients and to patients with c-Kit (CD117) positive unresectable
(inoperable) and/or metastatic malignant gastrointestinal stromal tumours (GISTs)
- cannot benefit from any reimbursement or insurance scheme
- are unable to pay for treatment privately as determined by pre-established socio-economic
criteria
- are in developing countries that have minimal reimbursement capabilities
- are in developing countries where regulatory approval for Glivec has been obtained
- are in developing countries where no generic versions of imatinib are available